CLINICAL DATA
The most relevant clinical trial of axitinib -AXIS -was a direct comparison with sorafenib after first-line therapy containing sunitinib, bevacizumab plus interferon-alfa, temsirolimus, or cytokines (Rini et al., 2011) . This enabled axitinib to be the first tyrosine kinase inhibitor to demonstrate superiority versus a comparator in its class. However, as the European Medicines Agency approved sorafenib just for patients whose "anticancer treatment with interferon alfa or interleukin 2 has failed or cannot be used" (EMA, 2014), the use of AXIS results in a context in which the standard first line is sunitinib is not straightforward. Everolimus efficacy was evaluated in the RECORD-1 clinical trial (Motzer et al., 2008) , a study without active comparator in patients previously treated with sunitinib, sorafenib, or both.
To allow a comparison between axitinib and everolimus in this clinical context, model authors developed a simulated treatment comparison (STC). The STC is a technique that allows to compare the effectiveness of drugs for which there are no direct comparison clinical trials nor is advisable to perform an indirect comparison due to lack of homogeneity among the cohorts followed in the original clinical trials (Ishak et al., 2011). Thus, using data from AXIS and RECORD-1 -but considering only patients previously treated with sunitinib and adjusting for cohort differences -it became possible to compare axitinib and everolimus. This STC allowed to estimate overall and progression free survival curves that are depicted in figures above. In each figure both Weibull and lognormal (best fit) curves are shown, being important to emphasize that incremental results do not depend on curve type.
This economic evaluation is based on a model developed by Evidera that allows to estimate incremental costs and quality adjusted life years (QALY) associated to the use of axitinib in patients with advanced renal cell carcinoma. The 4-week cycle model follows the standard structure of cost-effectiveness models in oncology, incorporating three health states: progression-free, progressed, and dead. A lifetime horizon is considered, assuming a 5% discount rate as stipulated in the Portugueses guidelines (Silva et al., 1998) . Despite being a survival model (i.e., a model based in overall and progression free survival curves) its structure can be illustrated as a Markov model. 
UTILITY SCORES
Utility score for the progression free health state were derived from AXIS results. It was taken into account that those patients who had not progressed but were off treatment experienced a higher quality of life. The utility score for progressed state was obtained on the literature (Remak et al., 2008) .
